Results 181 to 190 of about 63,127 (238)

Placebo Response in Phase II-III Symptom Intervention Studies: A Focus on Chemotherapy-Induced Peripheral Neuropathy and Associated Neuropathic Pain. [PDF]

Cancers (Basel)
Zahrieh D, Satele D, Haamankuli H, Wang XS, Le-Rademacher JG, Lee M, Liu H, Diaz-Cobo J, Shen SE, Chow S, Lustberg M, Ruddy KJ, Smith EML.   +12 more
europepmc   +1 more source

Prognostic and Predictive Role of Circulating Tumor DNA in Locally Advanced Rectal Cancer Managed With Total Neoadjuvant Therapy: A Systematic Review

Health Science Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background and Aims Circulating tumor DNA (ctDNA) has emerged as a promising biomarker of tumor burden and minimal residual disease. As total neoadjuvant therapy (TNT) increasingly supports organ‐preserving strategies in locally advanced rectal cancer (LARC), reliable markers of treatment response are needed.
Faizan Bashir, Qurat‐ul‐Aine Bhat, Jayden Allegakoen, Dorsa Shekouh, Sajida Zaiter   +4 more
wiley   +1 more source

PHGDH phosphorylation mediated by WNK1 serves as a dual marker of metabolic vulnerability and responsiveness to oxaliplatin treatment. [PDF]

Proc Natl Acad Sci U S A
Fang S, Jin G, Yan M, Song Y, Zhao S, Zhang C, Shao Y, Zhao K, Liu M, Wang Z, Jia X, Guo Q, Guo M, Wang M, Guo Z, Dong Z.   +15 more
europepmc   +1 more source

Deciphering the Formulation‐Dependent Neurotoxicity of Irinotecan: An Integrated Pharmacovigilance and Mechanistic Study

Journal of Biochemical and Molecular Toxicology, Volume 40, Issue 8, August 2026.
Overall workflow of the study, from computational toxicology screening and FAERS‐based data mining to mechanistic prediction of neurotoxicity of irinotecan. ABSTRACT Irinotecan is a key chemotherapeutic agent, but its neurotoxicity limits its utility.
Cheng Shen, Wei Ma, Jing Lu, Yongbo Tang, Wei Cao   +4 more
wiley   +1 more source

Advances in research on circadian rhythms and colorectal cancer. [PDF]

BMC Med Genomics
Jia L, Zhu M, Wu X, Zheng W, Zhang Y, Xiao J.   +5 more
europepmc   +1 more source

Beyond a Metabolite: Lactylation as a Pivotal Regulator of Colorectal Cancer Pathogenesis and Treatment Resistance

Journal of Biochemical and Molecular Toxicology, Volume 40, Issue 8, August 2026.
This review elucidates how lactylation, a novel histone modification driven by lactate, regulates colorectal cancer pathogenesis. We summarize its roles in tumor progression, metastasis, stemness, immunosuppression, and therapy resistance, and discusses the promising therapeutic strategies of targeting the lactylation pathway.
Shuilan Yao, Yun Liang, Xinwen Liang, Qisheng Su, Xiaohong Li   +4 more
wiley   +1 more source

TACE Combined with Ralox-HAIC (Oxaliplatin Puls Raltitrexed) and System Therapy in Patients with Unresectable Hepatocellular Carcinoma. [PDF]

J Hepatocell Carcinoma
Liu R, Cao G, Li L, Liu J, Cao H, Xing M, Feng Y, Li Z, Wang B.   +8 more
europepmc   +1 more source

A Real‐World Study Characterizing a US Population of Patients Receiving Rituximab With Gemcitabine and Oxaliplatin for Relapsed or Refractory Large B‐Cell Lymphoma

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Introduction Data for the use of rituximab, gemcitabine, and oxaliplatin (R‐GemOx) for relapsed/refractory (R/R) large B‐cell lymphoma (LBCL) in the United States are limited. This retrospective observational study characterizes R‐GemOx treatment patterns and outcomes among patients with R/R LBCL from the nationwide, longitudinal Flatiron ...
L. Elizabeth Budde, Adam J. Olszewski, Bei Hu, Nikesh N. Shah, Connie Lee Batlevi, Shen Yin, Iris To, Michael C. Wei, Martine Joanna Kallemeijn, Lisa Musick, Linda Lundberg, Natasha Shamas, Mark Dixon, Navdeep Pal, Ashwini Shewade, Jason Westin   +15 more
wiley   +1 more source

Comparative efficacy and safety of systemic therapies in transplant-eligible and ineligible relapsed/refractory large B-cell lymphoma: a Bayesian network meta-analysis. [PDF]

Transl Cancer Res
Huang L, Chen K, Wang M, Guo C, Li Y, Yu Q, Liu Z, Li Z.   +7 more
europepmc   +1 more source

The Dual Role of the Gut Microbiota in Cancer Chemoresistance

MicrobiologyOpen, Volume 15, Issue 4, August 2026.
Comparison between Microbiota and Cancer therapy. ABSTRACT Chemoresistance is one of the primary reasons that cancer chemotherapy fails to deliver successful treatment outcomes and contributes to poor overall survival rates for patients with cancer. New research has begun to shed light on the effects of the gut microbiome (GM).
Hamed Tahmasebi, Aisa Bahar, Meisam Khazaei, Mohammad Reza Arabestani   +3 more
wiley   +1 more source